William Renthal
Boston, MANPI 1598064883
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $16,875 of the $16,970 with a category attached, or 99.4%. AbbVie accounts for 78.9% of it on its own, with 2 other manufacturers making up the rest.
Across 4 payments — averaging $4242.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$13K
- Eli Lilly$2K
- Averitas Pharma Inc.$2K
Across 7 payments — averaging $175,564 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$779K
- Pfizer$450K
What the payments were for
- Consulting fees$16,87599%
- Food & beverage$951%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 2 | $13,395 |
| Eli Lilly | 1 | $1,875 |
| Averitas Pharma Inc. | 1 | $1,700 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QULIPTA$13,300
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aimovig AutoinjectorErenumab-Aooe | 41 | $35,264 |
| Nurtec OdtRimegepant Sulfate | 16 | $21,164 |
| Topiramate | 15 | $171 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.